share_log

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

Benzinga ·  Dec 14, 2023 06:36

Guggenheim analyst Subbu Nambi initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Buy rating and announces Price Target of $23.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment